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A central objective in organ transplantation and the treatment or prevention of autoimmune
disease is the achievement of antigen-speciﬁc immune tolerance. An additional challenge
in bone marrow transplantation for the treatment of hematological malignancies is the
prevention of graft-vs-host disease (GVHD) while maintaining graft-vs-tumor activity.
Interestingly, CD4−CD8− (double negative, DN) T cells, which exhibit a unique antigen-
speciﬁc immunoregulatory potential, appear to exhibit all of the properties to respond to
these challenges. Herein, we review the therapeutic potential of immunoregulatory DN
T cells in various immunopathological settings, including graft tolerance, GVHD, cancer,
and autoimmunity.
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INTRODUCTION
CD4−CD8− double negative (DN)T cells compose approximately
1–3% of total T cells in both mice and humans (Strober et al.,
1989; Abraham et al., 1992; Fischer et al., 2005). Phenotypically,
this rare T cell subset expresses a polyclonal αβT cell receptor
(TCR) repertoire, lacks the expression of Foxp3 as well as natural
killer (NK) cell markers and mostly presents with a naïve T cell
phenotype (recently reviewed; Hillhouse and Lesage, 2012). Inter-
estingly, their distinct phenotype, namely the lack of CD4 andCD8
co-receptors, is also believed to inﬂuence themethod bywhichDN
T cells recognize antigens and subsequently signal through their
TCR. In fact, major histocompatibility complex (MHC) restric-
tion is the cardinal feature of antigen recognition by T cells, where
the CD4 and CD8 co-receptors respectively facilitate the interac-
tion with MHC class II and I molecules. As DN T cells lack both
CD4 and CD8 co-receptors, the means by which the αβTCR on
the DN T cell recognizes MHC ligands with sufﬁcient afﬁnity and
avidity to provide activation of DN T cells is unclear. It has been
recently proposed that DN T cells recognize non-MHC ligands.
Indeed, using quad-deﬁcient mice that lack the expression of CD4
andCD8 co-receptors as well asMHCclass I and II expression,Van
Laethem et al. (2007) demonstrated that T cell development could
proceed in an MHC-independent manner. In fact, in the absence
of CD4 or CD8 co-receptor expression, the intracellular tyrosine
kinase Lck is no longer sequestered by the co-receptors and is thus
available to promote MHC-independent TCR signaling in thymo-
cytes. Subsequently, these thymocytes develop into mature DN T
cells that enter the periphery (Van Laethem et al., 2007). The abil-
ity of DN T cells to recognize non-MHC ligands is also supported
by the ﬁnding that mature DN T cells from quad-deﬁcient mice
proliferate vigorously against both MHC-sufﬁcient and MHC-
deﬁcient stimulator cells, but not in the absence of stimulator cells
(Van Laethem et al., 2007; Tikhonova et al., 2012). In fact, a recent
study has revealed the native self-protein CD155 as at least one
of the ligands recognized by quad-deﬁcient DN T cells via their
TCR and in the absence of antigen-processing (Tikhonova et al.,
2012). Therefore, the quad-deﬁcient mouse model has helped to
demonstrate that DN T cell differentiation can proceed in the thy-
mus and that DN T cell activation can occur independently of
co-receptors.
Double negative T cells have not only been observed in quad-
deﬁcient mice. For instance, an increased number of DN T cells
has been observed in many TCR transgenic models (Hillhouse
and Lesage, 2012). In these TCR transgenic models, due to forced
expression of an αβTCR transgene, the DN T cells do recognize
peptide–MHC complexes in the absence of co-receptor expres-
sion, suggesting that they exhibit a high afﬁnity for these antigenic
complexes. Moreover, in the absence of CD28 co-stimulation
which is required for clonal deletion of thymocytes (Punt et al.,
1994; Kishimoto and Sprent, 1997; Lesage et al., 1997), some
thymocytes that strongly recognize self-ligands survive negative
selection and ultimately develop into mature thymic DN T cells
(Pobezinsky et al., 2012). Together, these results suggest that DN
T cells may exhibit a relatively strong afﬁnity toward their cognate
ligands. This property is reminiscent of CD4+ Foxp3+ regula-
tory T cells (Tregs) and NKT cells, two immunoregulatory T cell
subsets which undergo agonist selection in the thymus (Baldwin
et al., 2004).
In addition to their distinct phenotype, DN T cells also exhibit
a unique antigen-speciﬁc immunoregulatory potential. Indeed,
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the immunoregulatory function of DN T cells was ﬁrst identi-
ﬁed almost 25 years ago, when Strober et al. (1989) successfully
cloned DN T cells from mice and subsequently demonstrated that
DN T cells mediate suppressor activity in a mixed-lymphocyte
reaction (MLR). Subsequently, Dr. Zhang’s group was the ﬁrst
to reveal the antigen-speciﬁc immunoregulatory potential of DN
T cells (Zhang et al., 2000). Speciﬁcally, they showed that DN T
cells from 2C TCR transgenic mice suppress the proliferation and
cytotoxic activity of 2C TCR CD8+ T cells in vitro, but not of
CD8+ T cells carrying other antigen speciﬁcities (Zhang et al.,
2000; Young and Zhang, 2002). Moreover, the antigen-speciﬁc
property of 2CTCRDNTcells is conferred, at least in part, by their
ability to acquire peptide–MHC complexes from antigen present-
ing cells (Zhang et al., 2000; Priatel et al., 2001; Young and Zhang,
2002; Ford McIntyre et al., 2008), a process known as trogocytosis
(Joly and Hudrisier, 2003). Notably, the in vitro antigen-speciﬁc
suppressive activity of 2C TCR DN T cells toward CD8+ T cells
was replicated using non-transgenic mice and humans (Zhang
et al., 2000; Young and Zhang, 2002; Fischer et al., 2005). Together,
these observations described a unique antigen-speciﬁc mode of
immunoregulation provided by DN T cells, leading to the antigen-
speciﬁc elimination of CD8+ T cells (Zhang et al., 2000;Young and
Zhang, 2002).
The immunoregulatory potential of DN T cells has since
been shown to extend beyond T cells. Indeed, TCR transgenic
and non-transgenic DN T cells can also inhibit NK cells (He
et al., 2007; Su et al., 2012), B cells (Zhang et al., 2006; Hill-
house et al., 2010; Ford McIntyre et al., 2011), and dendritic cells
(Gao et al., 2011). The combination of their distinct phenotypic
characteristics and their unique antigen-speciﬁc immunoregu-
latory properties toward multiple cellular targets has prompted
investigators to examine the role of DN T cells in various dis-
ease models. Herein, we will review the promising therapeutic
potential of DN T cells in the context of various disease set-
tings. More speciﬁcally, we will describe the impact of DN T cell
transfer on the induction of graft tolerance and the prevention of
autoimmunity aswell as present their dual role in preventing graft-
vs-host disease (GVHD) while promoting graft-vs-tumor (GvT)
responses.
GRAFT TOLERANCE
Although better known for their use in hematopoietic cell trans-
plantation to establish donor chimerismor treat neoplastic relapse,
donor leukocyte infusions (DLI) have also been shown to improve
allograft survival after solid organ transplantation (Fehr and
Sykes, 2004). Among possible mechanisms linking donor leuko-
cyte transfer and allograft tolerance, DN T cells have been shown
to increase allograft acceptance in various experimental settings.
In an attempt to understand why DLI has a positive outcome
on allograft survival, Dr. Zhang’s group took advantage of the
antigen-speciﬁc 2CTCR transgenicmodel (Yang et al., 1998,1999),
where the 2C TCR is alloreactive to the Ld MHC class I molecule
(Sha et al., 1988). Predictably, skin grafts bearing a single MHC-
mismatch at Ld are thus rapidly rejected by the 2C TCR recipient
mice due to the expression of Ld MHC class I molecule on the
donor skin cells (Yang et al., 1998, 1999; Figure 1A). However,
the injection of donor spleen cells to the 2C TCR recipient mice
prior to the skin graft efﬁciently induced antigen-speciﬁc allograft
tolerance (Yang et al., 1998, 1999; Figure 1B). The antigen-speciﬁc
tolerance to skin allografts induced by the transfer of donor T
cells was proposed to be mediated by 2C TCR transgenic DN
T cells as only the 2C TCR transgenic DN T cell subset, but
not the 2C CD4+ or 2C CD8+ T cell subset, was able to sup-
press an MLR response in vitro (Zhang et al., 2000). Accordingly,
Zhang’s group showed that the injection of 2C TCR F1 DN T cell
clones was sufﬁcient to induce both prolonged survival of both
skin and cardiac allografts (Zhang et al., 2000; Chen et al., 2003b;
Figure 1C). Importantly, the allograft tolerance was antigen-
speciﬁc, as full MHC-mismatched third party grafts were rapidly
rejected (Zhang et al., 2000; Figure 1C). Collectively, these data
demonstrate that 2C DN T cells are sufﬁcient to induce both
skin and cardiac allograft survival, suggesting that immunoreg-
ulatory DN T cells contribute to the beneﬁts of DLI on allograft
survival.
To further understand the mechanism by which 2C DN T cells
promote antigen-speciﬁc allograft tolerance, Young et al. (2002)
undertook the examination of the leukocytes found within the
tolerated skin grafts. In doing so, they discovered that 2C DN T
cells are the predominant leukocyte foundwithin the accepted skin
allografts. Moreover, the 2C DN T cells isolated from mice which
had received donor spleen cells prior to the skin graft demonstrate
an enhanced suppressive function toward 2C CD8+ T cells in vitro
(Young et al., 2002). Finally, the comparison of transcriptome pro-
ﬁles between 2C TCR F1 DN T cells clones that are able or unable
to confer cardiac allograft tolerance revealed FcRγ as a potential
molecule involved in deﬁning the tolerogenic potential of 2C DN
T cells (Lee et al., 2005). The importance of FcRγ expression on 2C
DNTcells for the inductionof allograft tolerancewas conﬁrmed as
the adoptive transfer of FcRγ-sufﬁcient, but not FcRγ-deﬁcient,
2C DN T cells prior to transplantation increased skin allograft
survival (Thomson et al., 2006). Altogether, these results demon-
strate that 2C DN T cells participate in allograft tolerance, likely
by inhibiting pathogenic 2C CD8+ T cell responses, at least in
the MHC class I-restricted graft tolerance model (Hillhouse and
Lesage, 2012).
Importantly, these observations were not limited to the 2CTCR
transgenic setting. Indeed, the injection of allogeneic donor spleen
cells bearing a single MHC class I mismatch prior to skin trans-
plantation in the non-transgenic setting also resulted in prolonged
allograft survival (Yang et al., 1999; Young et al., 2002; Zhang et al.,
2002). Analogous to the 2C TCR model, DN T cells from non-
transgenic mice that are activated in vivo following the injection
of donor spleen cells preferentially accumulate within the skin
allograft and eliminate CD8+ T cells in an antigen-speciﬁc man-
ner in vitro (Young et al., 2002). In a full MHC-mismatch heart
allograft, injection of non-transgenic DN T cells further pro-
moted rapamycin-induced graft tolerance (Zhang et al., 2011b). In
addition, in vitro-generated DN T cells can also provide antigen-
speciﬁc skin and pancreatic islet allograft tolerance (Zhang et al.,
2007, 2011a). Moreover, with regards to xenografts, the injection
of non-transgenic rat donor spleen cells in mice prevented CD4+
T cell-mediated cardiac xenograft rejection (Chen et al., 2003a,
2005). Similar to the transgenic setting, xenograft tolerance was
induced by DN T cells, as the transfer of DN T cells that had
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FIGURE 1 | Induction of allograft tolerance by the pre-transplantation
infusion of donor-specific spleen cells or DNT cells.This model takes
advantage of the antigen-speciﬁc 2CTCR transgenic system and skin grafts to
facilitate the study of allograft tolerance, where the 2CTCR transgene is
alloreactive to the Ld MHC class I molecule. (A) C57BL/6 (H2b) mice are bred
to BALB/c (H2d) mice to generate F1 mice (H2b,d) thus bearing the Ld MHC
molecule (black mouse). C57BL/6 2C transgenic mice (H-2b) are bred to
BALB/c (H2dm2 ) mice, which are a BALB/c Ld loss mutant (H2d, Ld−;
Rubocki et al., 1986), to generate 2CF1 mice (H2b,d, Ld−) bearing the anti-Ld
TCR (white mouse). Due to a single MHC-mismatch, skin grafts from Ld+ F1
mice are rapidly rejected by the 2CF1 mice. (B) However, the transfer of
donor spleen cells from Ld+F1 mice to 2CF1 mice (Ld−) prior to the Ld+ skin
graft transplantation results in graft survival. (C) Immunoregulatory 2C DNT
cell clones obtained from 2CF1TCR transgenic mice (Ld−) prevent the
rejection of single MHC-mismatch, allogeneic (Ld+, in black) skin grafts.
However, full MHC-mismatch, third party grafts (in gray) were rejected.
been isolated from mice which had received xenogeneic donor
spleen cells, was sufﬁcient to ensure cardiac xenograft tolerance
(Chen et al., 2003a). In this xenogeneic model, DN T cells efﬁ-
ciently suppressed the proliferation of both CD4+ and CD8+ T
cell anti-donor reactive cells (Chen et al., 2003a, 2005). Using a
variant of this cardiac xenograft model, it was also shown that
DN T cells can eliminate B cells, leading to a reduction in anti-
donor-speciﬁc antibody levels and delayed graft rejection (Ma
et al., 2008). Taken together, these ﬁndings suggest that, as opposed
to the MHC class I-restricted 2C TCR DN T cells, DN T cells from
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non-transgenic mice can suppress CD4+ and CD8+ T cells as
well as B cells in an antigen-speciﬁc manner and potently sup-
press both skin and cardiac allograft, as well as cardiac xenograft,
rejection.
Fas–FasL interactions have been proposed as the molecular
mechanismbywhichDNTcells eliminate anti-donorT cells, while
the elimination of B cells is considered to be perforin-mediated
(Zhang et al., 2000, 2006; Priatel et al., 2001; Ma et al., 2008; Ford
McIntyre et al., 2011). Interestingly, an accumulation of DN T
cells is observed in both Fas- and FasL-deﬁcient mice (Watanabe-
Fukunaga et al., 1992; Takahashi et al., 1994), suggesting that the
Fas–FasL pathway may regulate the number of DN T cells in vivo.
By taking advantage of lpr mice, which exhibit a Fas-deﬁciency,
Ford et al. (2002) demonstrated that DN T cells from lpr mice
can mediate their immunoregulatory function through the Fas
pathway as long as the target T cells express a functional Fas pro-
tein. Indeed, DN T cells from lpr mice could effectively delay both
single MHC class I- and single MHC class II-mismatched skin
allograft rejection (Ford et al., 2002). In summary, DN T cells can
clearly induce an antigen-speciﬁc tolerance to both allografts and
xenografts by eliminating or inhibiting the function of various
target immune cells.
AUTOIMMUNITY
The antigen-speciﬁc immunoregulatory potential of DN T cells
in graft tolerance suggests that they may also participate in the
induction of immune tolerance in various autoimmune settings.
As a result, the role of DN T cells has been mostly explored
in autoimmune lymphoproliferative syndrome (ALPS), systemic
lupus erythematosus (SLE) and mouse models of type 1 diabetes
(T1D), as described below.
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME
Autoimmune lymphoproliferative syndrome is a rare disorder
characterized by mutations in either Fas or FasL (Rieux-Laucat
et al., 1995; Del-Rey et al., 2006), which results in defective
Fas-mediated apoptosis and, consequently, the abnormal accu-
mulation of activated lymphocytes. ALPS patients on average
present with a 10-fold increase in DN T cell proportion (Bleesing
et al., 2001a; Bristeau-Leprince et al., 2008; Magerus-Chatinet
et al., 2009) and a sizeable proportion of DN T cells can also be
found in the lymphoid organs of the murine models for ALPS,
namely lpr/lpr (Fas-deﬁcient) and gld/gld (FasL-deﬁcient) mice
(Cohen and Eisenberg, 1992; Watanabe-Fukunaga et al., 1992;
Takahashi et al., 1994). Moreover, a greater proportion of DN
T cells from ALPS patients, in comparison to healthy controls,
express the B cell antigen, B220 (Bleesing et al., 2001a), which is
consistent with ﬁndings in lpr/lpr mice (Davidson et al., 1986).
Accordingly, B220 expression is a general feature of proliferat-
ing T cells (Bleesing et al., 2001b), which explains why B220+
DN T cells can also be found in healthy individuals. Although
it cannot be denied that a drastic increase in the proportion
of DN T cells can be observed in lpr/lpr and gld/gld mice, as
well as ALPS patients, there is arguably no evidence to sug-
gest that the accumulation of DN T cells is pathogenic. Indeed,
Fas-deﬁcient DN T cells found in lpr/lpr mice, but not FasL-
deﬁcient DN T cells found in gld/gld mice, remain functional
and, as mentioned above, can efﬁciently induce graft tolerance
(Ford et al., 2002). Hence, as DN T cell-mediated suppression
depends on interactions between FasL on DN T cells and Fas
on target T cells (Ford et al., 2002), it has been suggested that
DN T cells accumulate in an attempt to compensate for their
inability to suppress autoimmune T cells in lpr/lpr mice (Ford
et al., 2002).
SYSTEMIC LUPUS ERYTHEMATOSUS
Similar to ALPS patients, DN T cells are also found in greater
numbers in the peripheral blood of patients with SLE (Crispin
et al., 2008). However, in the case of SLE, these DN T cells are
major producers of IL-17 (Crispin and Tsokos, 2009), which is
pathogenic in this disease (Wong et al., 2000; Doreau et al., 2009).
Moreover, IL-17-producing DN T cells can be found in the kid-
ney sections of patients with lupus nephritis (Crispin et al., 2008).
These results lead Crispin et al. (2008) to suggest that DN T cells
themselves are pathogenic in SLE. Yet, it must be noted that, in
these studies, DN T cells were deﬁned as CD4−CD8−TCRαβ+
cells, which may contain contaminating CD4−CD8− NKT cells
expressing a TCR restricted to CD1d molecules (Hillhouse and
Lesage, 2012). Of relevance, NKT cells do indeed include a sub-
set of CD4−NK1.1− IL-17-producing cells (Coquet et al., 2008).
Moreover, NKT cells have been implicated in SLE pathogenesis
where the activation of NKT cells through the administration of
α-GalCer exacerbated disease whereas the inhibition of NKT cell
activation using an anti-CD1d blocking antibody resulted in dis-
ease amelioration (Zeng et al., 2003). Thus, NKT cells cannot be
ruled out as the true IL-17-producing cell subset in this particular
study. Nevertheless, IL-17-producing DN T cells have also been
shown to play a protective role against bacterial infections (Cow-
ley et al., 2005; Riol-Blanco et al., 2010). Altogether, an uncertain,
yet possible, role for DN T cells in patients with SLE remains to be
deﬁned.
TYPE 1 DIABETES
Type 1 diabetes occurs as a result of the antigen-speciﬁc elimina-
tion of pancreatic insulin-producing β cells. It thus presents as a
relevant model to investigate the antigen-speciﬁc immunoregula-
tory potential of DN T cells.
The tolerogenic role of DN T cells in the prevention of
T1D was ﬁrst revealed using the P14/RIP-gp transgenic mouse
model (Ohashi et al., 1991), where the MHC class I-restricted P14
TCR transgene recognizes the lymphocytic choriomeningitis virus
(LCMV) protein, gp33–41 (gp33), which is expressed under the
rat insulin promoter (RIP) forcing its expression in the pancreatic
tissue. RIP-gp mice that are crossed to P14 mice carry a very high
percentage of gp33-reactive T cells, yet the resulting P14 TCR:RIP-
gp mice do not spontaneously develop diabetes on the C57BL/6
background (Ohashi et al., 1991). Indeed, P14/RIP-gp transgenic
mice rapidly develop diabetes upon treatment with gp33 peptide
and anti-CD40 agonistic antibody, which results in the inﬁltration
of pancreatic islets by activated CD8+ T cells and the subsequent
destruction of the insulin-producing β cells (Garza et al., 2000).
Using this model, it was shown that the transfer of gp33 activated
P14 DN T cells 1 day prior to diabetes induction can inhibit dia-
betes development (Ford et al., 2007). These results were the ﬁrst
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indication that DN T cells may participate in the prevention of a
CD8+ T cell-driven T1D pathology, further lending support for a
potential role for DN T cells toward the elimination of CD8+ T
cells in vivo.
The protective role of DN T cells in diabetes development
was further investigated by our group using the 3A9 TCR:insHEL
transgenic system, in which the MHC class II-restricted 3A9 TCR
transgene recognizes a peptide from hen egg lysozyme (HEL) pre-
sented by I-Ak, while the insHEL transgene forces the expression
of HEL in the pancreatic tissue. Although TCR:insHEL BALB.K
mice are relatively resistant to T1D, CD47-deﬁcient TCR:insHEL
BALB.K mice have a high and spontaneous incidence of diabetes.
Using this model of spontaneous T1D, a single transfer of 3A9
DN T cells in the TCR:insHEL CD47-deﬁcient BALB.K trans-
genic model was able to signiﬁcantly inhibit the development
of T1D (Dugas et al., 2010). Notably, a 3A9 DN T cell trans-
fer led to a signiﬁcant reduction in antigen-speciﬁc autoantibody
serum levels (Dugas et al., 2010), suggesting the in vivo elimina-
tion of autoreactive B cells. We subsequently demonstrated that
3A9 DN T cells efﬁciently eliminate HEL-loaded B cells in vitro
(Hillhouse et al., 2010). Although this model is imperfect in that it
is a CD47-deﬁcient model, where CD47 is implicated in apopto-
sis, phagocytosis, cell migration, and T cell responses (Oldenborg,
2004; Chao et al., 2012), it is nevertheless a spontaneous model
of T1D wherein the results complement the ﬁndings of Ford et al.
(2007) suggesting that DN T cells may be of therapeutic interest
for T1D.
Interestingly, the proportion of DN T cells is signiﬁcantly
reduced in diabetes-prone mice in comparison to diabetes-
resistant mice in both the transgenic and non-transgenic systems
(Dugas et al., 2010). It is of relevance that both the non-transgenic
and TCR:insHEL transgenic diabetes-prone non-obese diabetic
(NOD) mouse models exhibit a low number of DN T cells rel-
ative to other diabetes-resistant strains as it suggests that low
DN T cell numbers are associated with diabetes susceptibility.
Despite a reduction in cell number, 3A9 DN T cells from 3A9 TCR
transgenicNOD.H2k mice carrying adiabetes-prone genetic back-
ground (Lesage et al., 2002) exhibit an equally potent cytotoxic
function in comparison to 3A9 DN T cells from diabetes-resistant
3A9 TCR transgenic B10.Br mice (Hillhouse et al., 2010). There-
fore, the association of DN T cells with diabetes susceptibility is
due to a deﬁciency in DN T cell number rather than function.
Altogether, these results further suggest that the restoration of
DN T cell number can prevent T1D development in otherwise
diabetes-susceptible mice.
The role of DN T cells in the prevention of T1D was also
recently evaluated using non-transgenic DN T cells. Indeed, Dun-
can et al. (2010) have demonstrated that non-transgenic DN T
cells can protect from autoimmune diabetes. Speciﬁcally, dia-
betes induction was inhibited if DN T cells were transferred
into recipient NOD.SCID (severe combined immunodeﬁciency)
mice 1 month prior to co-infusion with diabetogenic spleen cells,
whereas the simultaneous co-infusion of diabetogenic spleen cells
and DN T cells does not protect from disease (Duncan et al.,
2010). However, as NKT cells were not fully excluded from the
cellular preparation, additional studies using NKT cell-depleted
non-transgenic DN T cells are warranted to ﬁrmly establish the
biological function of these cells in the prevention of autoim-
mune diabetes in diabetes-susceptibleNODmice. Notably, further
investigation is still needed to verify the role of DN T cells in
T1Ddevelopment using non-lymphopenicNODmice, thus under
more physiological and spontaneous conditions. Nevertheless,
these results do provide useful information regarding the critical
time of treatment initiation aswell as evidence that non-transgenic
DN T cells may exhibit the potential to inhibit T1D development
in non-transgenic mice.
A more recent study further evaluated the role of non-
transgenic DN T cells in T1D. Here, it was shown that 50%
of CD4+ T cells isolated from an MLR had been converted to
CD4−CD8− T cells. These CD4+ T cell-converted DN T cells
sorted by ﬂow cytometry were shown to delay T1D onset when
adoptively transferred to NOD.SCID mice in combination with
diabetogenic T cells (Zhang et al., 2011a). This delay was further
enhanced when using GAD65 antigen to stimulate the CD4+ T
cells, thereby likely generating a higher proportion of GAD65-
speciﬁc DN T cells. Moreover, a single transfer of GAD65-speciﬁc
DN T cells speciﬁcity was able to prevent diabetes development in
5-week-old NOD mice and decrease blood glucose levels in new-
onset diabetic NOD mice (Zhang et al., 2011a). Therefore, this
study offers a potentially translatable therapeutic approach for the
generation of antigen-speciﬁc DNT cells in the prevention and
treatment of T1D.
Altogether, these ﬁndings point toward an antigen-speciﬁc
immunoregulatory role for DN T cells in autoimmune diseases.
The therapeutic potential of these cells certainly merits further
investigation in additional pre-clinical models.
GRAFT-vs-HOST DISEASE AND CANCER
In the treatment of hematological malignancies, allogeneic
hematopoietic cell transplantation (AHCT) can eradicate several
blood cancers that are incurable by chemotherapy alone. Despite
indisputable successes, the efﬁcacy of AHCT is still limited by
cancer recurrence and the development of GVHD (Raiola et al.,
2003). While the acute form of GVHD is triggered by direct T cell
recognition of histocompatibility antigens, the pathophysiology of
chronicGVHDremainsmore elusive and relies on several immune
cell types (Shlomchik, 2007). Currently, 40–80% of patients
develop chronicGVHDafterAHCT,whichbrings substantialmor-
bidity and mortality (Lee, 2005). Several lines of evidence suggest
that immunoregulatory immune cells are paramount to GVHD
prevention. Indeed, both CD4+ Tregs and NKT cells have been
suggested as major contributors of allotolerance in hematopoi-
etic cell transplantation (Hoffmann et al., 2002; Kohrt et al., 2010;
Di Ianni et al., 2011; Chaidos et al., 2012). However, the ability
of Tregs to maintain their anti-tumor T cell responses remains
controversial (Onizuka et al., 1999; Shimizu et al., 1999; Liyanage
et al., 2002; Somasundaram et al., 2002; Kohrt et al., 2010). Here,
we review the potential of DN T cells at inhibiting GVHD while
speciﬁcally promoting anti-tumor responses.
GRAFT-vs-HOST DISEASE
Mouse models of GVHD, although they admittedly do not fully
replicate human disease, facilitate the examination of the cellular
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process amid the allogeneic responses which give rise to a GVHD-
like pathology in vivo (Shlomchik, 2007). A potential role for DN
T cells in the prevention of GVHD can be traced back to over
two decades ago when Bruley-Rosset et al. (1990) demonstrated
that transfer of spleen cells from pre-immunized mice was able
to inhibit GVHD only when DN T cells were included in the
cellular preparations. Although the DN T cells were not void of
contaminating NKT cells, these results still suggested that DN T
cells play a role in GVHD prevention. Because of their prominent
antigen-speciﬁc immunoregulatory potential as well as their abil-
ity to promote allotolerance, the contribution of DN T cells at
preventing GVHD was later investigated using the 2C TCR sin-
gle MHC-mismatch model (Young et al., 2003a), for which DN
T cells have been shown to effectively prevent allograft rejection
(Zhang et al., 2000;Young et al., 2002; Chen et al., 2003b; Figure 1).
Speciﬁcally, mice bearing a single MHC-mismatch (Ld) injected
with Ld-speciﬁc 2C TCR transgenic spleen cells survived for more
than 150 days without any clinical or histological signs of acute
or chronic GVHD (Young et al., 2003a; Figure 2A). The tolerance
of donor spleen cells may be explained, at least in part, by the
accumulation of 2C TCR DN T cells, which can effectively inhibit
pathogenic CD8+ T cell responses, in recipient mice (Young et al.,
2003a). Subsequently, the role of non-transgenic DN T cells in
both parent to F1 and fullyMHC-mismatched bonemarrow (BM)
transplantation following either a myeloablative (He et al., 2007)
or non-myeloablative regimen (Su et al., 2012) was investigated
(Figure 2B). In stark contrast to CD4+ and CD8+ T cells, the
co-injection of non-transgenic DN T cells with T cell-depleted
BM into a sublethally irradiated host ensured prolonged recipi-
ent survival in the absence of clinical signs of GVHD (He et al.,
2007; Su et al., 2012; Figure 2B), indicating that DN T cells are
not alloreactive nor pathogenic in this context. Moreover, this
led to stable mixed chimerism and, as opposed to BM transplan-
tation alone, promoted donor allotolerance (He et al., 2007; Su
et al., 2012; Figure 2B). Together, these ﬁndings demonstrate that,
as opposed to CD4+ or CD8+ T cells, the transfer of allogeneic
DN T cells does not cause GVHD. Rather, DN T cells prevent
GVHD, induce mixed chimerism and promote donor-speciﬁc
allotolerance.
Notably, there is accrued evidence that DN T cells also prevent
GVHD in humans upon AHCT. Indeed, the stem cells used for
AHCT are currently most commonly obtained from the periph-
eral blood mononuclear cells of granulocyte colony-stimulating
factor (G-CSF)-treated donors, where G-CSF is used to mobi-
lize CD34+ hematopoietic stem cells into the blood (Shlomchik,
2007). Interestingly, in addition to skewing toward a Th2 pheno-
type, G-CSF treatment also results in an increase in the proportion
of immunoregulatory DN T cells in the blood (Kusnierz-Glaz
et al., 1997). The combination of these two phenotypes may
explain why the transfer of CD34+ stem cells isolated follow-
ing G-CSF treatment does not increase the incidence of acute
GVHD relative to classical BM transplants. More recently, two
studies also noted a clear correlation between an elevated propor-
tion of DN T cells and a low incidence of GVHD development
following AHCT (McIver et al., 2008; Ye et al., 2011). Together,
these observations support the view that human DN T cells may
prevent GVHD.
THE ANTI-TUMOR RESPONSE
In addition to preventing GVHD, DN T cells demonstrate an
anti-tumor activity without causing GVHD in recipient mice
(Young et al., 2001, 2003b). Indeed, >90% of sublethally irra-
diated immunodeﬁcient SCID mice that were co-infused with a
lethal dose of A20 lymphoma cells together with allogeneic 2C
TCR transgenic spleen cells survived indeﬁnitely in the absence of
GVHD. Interestingly, recipient mice exhibited a 15-fold increase
in the number of DN T cells in their spleen (Young et al., 2003b),
suggesting an association between DN T cells and the inhibition of
GVHD as well as tumor growth. Accordingly, Young et al. (2003b)
demonstrated that the injection of either 2C DN T cell clones
or non-transgenic DN T cells was sufﬁcient to prevent A20 lym-
phoma tumor growth, without inducing clinical or histological
signs of GVHD. Altogether, these results further demonstrate the
anti-tumoral potential of DN T cells.
To further deﬁne the potential use of DNTcells in the treatment
of hematological malignancies, Merims et al. (2011) performed
a pre-clinical study in acute myeloid leukemia (AML) patients
undergoing complete remission following standard chemother-
apy. In this study, they demonstrate that DN T cells can be
readily isolated from the blood of AML patients. Moreover,
the isolated DN T cells maintain their phenotype following
a proﬁcient cellular expansion reaching nearly 500-fold in 2
weeks (Merims et al., 2011). Of interest, the DN T cells isolated
and expanded in vitro demonstrated efﬁcient cytolytic activity
toward the autologous leukemic cells in six out of seven patients
(Merims et al., 2011). Importantly, the anti-tumoral activity of
DN T cells may extend beyond hematological malignancies, as
melanoma-reactive DN T cells have also been successfully isolated
from a previously immunized melanoma patient (Voelkl et al.,
2009). The mechanism by which DN T cells are able to confer
antigen-speciﬁc immune tolerance all the while providing an anti-
tumor response is counterintuitive and certainly merits further
investigation.
CONCLUSION
Immunoregulatory DN T cells, which compose approximately
1–3% of T cells in human PBMCs (Fischer et al., 2005), demon-
strate a unique antigen-speciﬁc therapeutic potential, such that
they provide a favorable outcome in graft tolerance, autoimmu-
nity and GVHD. In addition, DN T cells exhibit an interesting
anti-tumoral potential. This seemingly broad applicability of DN
T cells at conferring antigen-speciﬁc immune tolerance must be
interpreted with caution. Indeed, DN T cells compose a hetero-
geneous subset of cells, which include all CD4−CD8−CD3+ T
cell subsets, namely TCRγδ T cells, NKT cells and immunoregu-
latory TCRαβ DN T cells (Hillhouse and Lesage, 2012). Despite
the heterogeneity in the description of DN T cells in various stud-
ies, which do not always exclude TCRγδ and/or NKT cells, most
studies in TCR transgenic and non-transgenic mice as well as in
humans point toward an immunoregulatory role for DN T cells.
A few notable exceptions to this are the description of pathogenic
IL-17-producing DN T cells in SLE (Crispin and Tsokos, 2009)
and the characterization of IL-23 responsive DN T cells control-
ling bacterial infections (Cowley et al., 2005, 2010; Riol-Blanco
et al., 2010). Clearly, additional studies aimed at identifying
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FIGURE 2 | Double negativeT cells promote tolerance while inhibiting
GVHD. (A) Immunodeﬁcient SCID F1 mice (H2b,d, Ld+) were sublethally
irradiated and reconstituted with 2CF1 (H2b,dm2, Ld−) Ld-speciﬁc spleen
cells. Three weeks later, recipient mice were given skin grafts from F1 (Ld+,
in white) and full MHC-mismatch, third party (in gray) mice. The third party
skin graft was rejected, whereas the skin graft from the F1 (Ld+) donor
mouse was accepted. Importantly, the recipient mice showed no signs of
GVHD and exhibited a prominent increase in the levels of donor-derived DNT
cells over time. (B) BALB/c (H2d) mice underwent myeloablative (top panel,
sublethal irradiation) or non-myeloablative (bottom panel, busulfan treatment)
conditioning prior to being reconstituted with a combination of C57BL/6 (H2b)
DNT cells andT cell-depleted (TCD) C57BL/6 (H2b) bone marrow (BM) cells.
Subsequently, recipient mice received skin grafts from donor C57BL/6 (H2b,
in black) and third party (H2k, in gray) mice. Regardless of the type of
conditioning regimen utilized, the recipient mice accepted all C57BL/6 (H2b,
in black) donor grafts while third party (H2k, in gray) grafts were rejected.
unique markers for these unique cell types will help clarify which
speciﬁc cellular subset contributes to each speciﬁc biological
setting.
In conclusion, immunoregulatory DN T cells exhibit great
potential as a cellular therapy for various models of disease, with
exciting advances in the pre-clinical setting. As the function of
DN T cells is mainly antigen-speciﬁc, the use of DN T cells in
immunotherapy should lead to fewer side-effects and a decreased
risk of infections, which is a major concern in the application of
broad immunosuppressive regimens. Moreover,DNT cells exhibit
www.frontiersin.org January 2013 | Volume 4 | Article 6 | 7
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a potent immunosuppressive potential in multiple model systems,
from transplantation to autoimmunity, suggesting a vast array of
applicability of DN T cells in cellular therapy.
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